Efficacy of RTS,S Malaria Vaccines: Individual-participant Pooled Analysis of Phase 2 Data

Overview

Journal Lancet Infect Dis

Specialty Infectious Diseases

Date 2013 Mar 5

PMID 23454164

Citations 50

Authors

Philip Bejon

Michael T White

Ally Olotu

Kalifa Bojang

John P A Lusingu

Nahya Salim

Nekoye N Otsyula

Selidji T Agnandji

Kwaku Poku Asante

Seth Owusu-Agyei

Salim Abdulla

Azra C Ghani

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy of RTS,S/AS01 as a vaccine for malaria is being tested in a phase 3 clinical trial. Early results show significant, albeit partial, protection against clinical malaria and severe malaria. To ascertain variations in vaccine efficacy according to covariates such as transmission intensity, choice of adjuvant, age at vaccination, and bednet use, we did an individual-participant pooled analysis of phase 2 clinical data.

Methods: We analysed data from 11 different sites in Africa, including 4453 participants. We measured heterogeneity in vaccine efficacy by estimating the interactions between covariates and vaccination in pooled multivariable Cox regression and Poisson regression analyses. Endpoints for measurement of vaccine efficacy were infection, clinical malaria, severe malaria, and death. We defined transmission intensity levels according to the estimated local parasite prevalence in children aged 2-10 years (PrP₂₋₁₀), ranging from 5% to 80%. Choice of adjuvant was either AS01 or AS02.

Findings: Vaccine efficacy against all episodes of clinical malaria varied by transmission intensity (p=0·001). At low transmission (PrP₂₋₁₀ 10%) vaccine efficacy was 60% (95% CI 54 to 67), at moderate transmission (PrP₂₋₁₀ 20%) it was 41% (21 to 57), and at high transmission (PrP₂₋₁₀ 70%) the efficacy was 4% (-10 to 22). Vaccine efficacy also varied by adjuvant choice (p<0·0001)--eg, at low transmission (PrP₂₋₁₀ 10%), efficacy varied from 60% (95% CI 54 to 67) for AS01 to 47% (14 to 75) for AS02. Variations in efficacy by age at vaccination were of borderline significance (p=0·038), and bednet use and sex were not significant covariates. Vaccine efficacy (pooled across adjuvant choice and transmission intensity) varied significantly (p<0·0001) according to time since vaccination, from 36% efficacy (95% CI 24 to 45) at time of vaccination to 0% (-38 to 38) after 3 years.

Interpretation: Vaccine efficacy against clinical disease was of limited duration and was not detectable 3 years after vaccination. Furthermore, efficacy fell with increasing transmission intensity. Outcomes after vaccination cannot be gauged accurately on the basis of one pooled efficacy figure. However, predictions of public-health outcomes of vaccination will need to take account of variations in efficacy by transmission intensity and by time since vaccination.

Funding: Medical Research Council (UK); Bill & Melinda Gates Foundation Vaccine Modelling Initiative; Wellcome Trust.

Citing Articles

A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-Saharan African clinical trials.

Hamisi M, Asri N, Yassim A, Suppian R PLoS One. 2025; 20(1):e0317233.

PMID: 39854359 PMC: 11760592. DOI: 10.1371/journal.pone.0317233.

Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection.

Mukhiya R, Fleischmann W, Loughland J, Chan J, De Labastida Rivera F, Andrew D EBioMedicine. 2024; 109:105419.

PMID: 39490199 PMC: 11576503. DOI: 10.1016/j.ebiom.2024.105419.

Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention.

Wang L, Idris A, Kisalu N, Crompton P, Seder R Nat Immunol. 2024; 25(9):1530-1545.

PMID: 39198635 DOI: 10.1038/s41590-024-01938-2.

Poly I:C elicits broader and stronger humoral and cellular responses to a circumsporozoite protein malaria vaccine than Alhydrogel in mice.

Costa-Gouvea T, Francoso K, Marques R, Gimenez A, Faria A, Cariste L Front Immunol. 2024; 15:1331474.

PMID: 38650939 PMC: 11033515. DOI: 10.3389/fimmu.2024.1331474.

Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies.

Chutiyami M, Saravanakumar P, Bello U, Salihu D, Adeleye K, Kolo M Infection. 2024; 52(5):2007-2028.

PMID: 38441731 PMC: 11499420. DOI: 10.1007/s15010-024-02196-y.

References

Bejon P, Williams T, Liljander A, Noor A, Wambua J, Ogada E . Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med. 2010; 7(7):e1000304. PMC: 2897769. DOI: 10.1371/journal.pmed.1000304. View

Royston P, Reitz M, Atzpodien J . An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer. 2006; 94(12):1785-8. PMC: 2361333. DOI: 10.1038/sj.bjc.6603192. View

Mabunda S, Aponte J, Tiago A, Alonso P . A country-wide malaria survey in Mozambique. II. Malaria attributable proportion of fever and establishment of malaria case definition in children across different epidemiological settings. Malar J. 2009; 8:74. PMC: 2678146. DOI: 10.1186/1475-2875-8-74. View

Polhemus M, Remich S, Ogutu B, Waitumbi J, Otieno L, Apollo S . Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS One. 2009; 4(7):e6465. PMC: 2714466. DOI: 10.1371/journal.pone.0006465. View

Ceesay S, Casals-Pascual C, Erskine J, Anya S, Duah N, Fulford A . Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis. Lancet. 2008; 372(9649):1545-54. PMC: 2607025. DOI: 10.1016/S0140-6736(08)61654-2. View

Kester K, Cummings J, Ofori-Anyinam O, Ockenhouse C, Krzych U, Moris P . Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200(3):337-46. DOI: 10.1086/600120. View

Agnandji S, Lell B, Soulanoudjingar S, Fernandes J, Abossolo B, Conzelmann C . First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011; 365(20):1863-75. DOI: 10.1056/NEJMoa1102287. View

Aponte J, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J . Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet. 2007; 370(9598):1543-51. DOI: 10.1016/S0140-6736(07)61542-6. View

Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J . Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 2008; 359(24):2521-32. PMC: 2655100. DOI: 10.1056/NEJMoa0807381. View

10.

Snow R, Omumbo J, Lowe B, Molyneux C, Obiero J, Palmer A . Relation between severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa. Lancet. 1997; 349(9066):1650-4. DOI: 10.1016/S0140-6736(97)02038-2. View

11.

Bojang K, Milligan P, Pinder M, Vigneron L, Alloueche A, Kester K . Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001; 358(9297):1927-34. DOI: 10.1016/S0140-6736(01)06957-4. View

12.

Olotu A, Fegan G, Williams T, Sasi P, Ogada E, Bauni E . Defining clinical malaria: the specificity and incidence of endpoints from active and passive surveillance of children in rural Kenya. PLoS One. 2010; 5(12):e15569. PMC: 3002959. DOI: 10.1371/journal.pone.0015569. View

13.

Moorthy V, Ballou W . Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J. 2010; 8:312. PMC: 2806383. DOI: 10.1186/1475-2875-8-312. View

14.

Maire N, Aponte J, Ross A, Thompson R, Alonso P, Utzinger J . Modeling a field trial of the RTS,S/AS02A malaria vaccine. Am J Trop Med Hyg. 2006; 75(2 Suppl):104-10. DOI: 10.4269/ajtmh.2006.75.104. View

15.

Asante K, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S . Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011; 11(10):741-9. DOI: 10.1016/S1473-3099(11)70100-1. View

16.

White M, Griffin J, Drakeley C, Ghani A . Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar J. 2010; 9:82. PMC: 2851701. DOI: 10.1186/1475-2875-9-82. View

17.

Abdulla S, Oberholzer R, Juma O, Kubhoja S, Machera F, Membi C . Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med. 2008; 359(24):2533-44. DOI: 10.1056/NEJMoa0807773. View

18.

Halloran M, Haber M, Longini Jr I . Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol. 1992; 136(3):328-43. DOI: 10.1093/oxfordjournals.aje.a116498. View

19.

OMeara W, Bejon P, Mwangi T, Okiro E, Peshu N, Snow R . Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet. 2008; 372(9649):1555-62. PMC: 2607008. DOI: 10.1016/S0140-6736(08)61655-4. View

20.

Sacarlal J, Aide P, Aponte J, Renom M, Leach A, Mandomando I . Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis. 2009; 200(3):329-36. DOI: 10.1086/600119. View